GE HealthCare Technologies Inc. (GEHC) climbs on deep earnings
GE HealthCare Technologies Inc. (GEHC) climbs after a detailed earnings beat, with EPS and revenue topping estimates, orders and backlog hitting records, and imaging and pharmaceutical diagnostics offsetting weakness in Patient Care Solutions. The full analysis looks beyond the headline move to segment trends, margins, and the turnaround path ahead.
GE HealthCare Technologies Inc. (GEHC) delivered a clean second-quarter beat, with adjusted EPS of $1.13 and revenue of $5.29 billion topping estimates and sending the stock up 10.06%. The strongest signals came from 11.1% order growth, a record $23.9 billion backlog, and solid momentum in imaging and pharmaceutical diagnostics, which outweighed a sharp decline in Patient Care Solutions. For investors, the quarter supports the bull case on demand and backlog conversion, but PCS execution and margin pressure remain the key risks to the turnaround.
GE HealthCare Technologies Inc. (GEHC) Climbs on Earnings
GEHC climbs 10.06% to $70.56 after GE HealthCare Technologies Inc. posted second-quarter adjusted EPS of $1.13 and revenue of $5.29B. Both figures beat estimates, while record orders and backlog gave investors a stronger growth signal despite a sharp decline in Patient Care Solutions.
The market reaction was forceful, with 11,630,444 shares changing hands against an average volume of 5,434,822. Still, the GEHC earnings story has two moving parts: strong demand in imaging and pharmaceutical diagnostics, alongside a PCS turnaround that remains unfinished.
Key Takeaways
Adjusted EPS reached $1.13, above the $1.04 estimate. Revenue came in at $5.29B, ahead of the $5.26B estimate.
Pharmaceutical Diagnostics led segment growth with 14.6% organic revenue growth and a 29.6% EBIT margin.
Advanced Imaging Solutions delivered 5% organic revenue growth and expanded EBIT margin by 90 basis points year over year.
Patient Care Solutions organic revenue fell 13.5%, and segment EBIT was negative. Management expects sequential improvement in the second half.
Orders increased 11.1%, book-to-bill reached 1.15x, and backlog rose $2.6B year over year to a record $23.9B.
The analyst consensus remains Buy, with 10 Buy ratings and 8 Holds. Before earnings, UBS held a Neutral rating with a $69 target, while BTIG cut its target by $5.
GE HealthCare generated $5.29B in second-quarter revenue, representing 3.5% organic growth year over year. Revenue increased from $5.13B in the March quarter and $5.01B in the June 2025 quarter. On a reported basis, the company recorded growth across all regions.
The mix also improved in important areas. Product revenue grew 4.7%, while service revenue increased 7.7%. Service growth received help from operating performance and the Intelerad acquisition. That service base matters because recurring revenue tends to make a medical technology business less dependent on individual equipment orders.
Advanced Imaging Solutions, which combines the former Imaging and Advanced Visualization Solutions businesses, posted 5% organic revenue growth. Cardiovascular and interventional solutions, CT, and molecular imaging drove the result. EBIT margin expanded 90 basis points year over year through volume and price, partly offset by inflation.
Pharmaceutical Diagnostics was the standout. Organic revenue increased 14.6%, supported by contrast media pricing and volume, plus strong growth in U.S. radiopharmaceuticals. Its 29.6% EBIT margin improved 30 basis points. Vizamyl delivered double-digit revenue growth, and Flyrcado doses reached 545 for the week ending July 24, about 40% above April levels.
Patient Care Solutions was the weak link. Organic revenue declined 13.5%, and segment EBIT moved into negative territory. Fulfillment problems affected monitoring and anesthesia products. GEHC has launched initiatives to improve shipment velocity, supply execution, and backlog conversion. Management also began a strategic review that includes continued ownership, a sale, and other value-enhancing transactions.
Adjusted EBIT was $750M, producing a 14.2% margin. That margin fell 40 basis points year over year. PCS weakness and higher costs for memory chips, oil, freight, and other components created pressure. Volume growth and commercial execution provided an offset, while price and cost actions started to take hold during the quarter.
Adjusted EPS rose 6.6% year over year to $1.13. The result included a $0.04 benefit from tariff refunds and a $0.02 benefit from a lower tax rate. The recent earnings history lists EPS at $0.99 on April 29 and $1.44 on February 4, placing the current result above April's figure but below February's peak.
Cash flow requires a more careful reading. Free cash flow was $68M and included $107M of tariff refunds. Working capital investments and capital spending offset that benefit. In adjusted EBIT, GEHC recognized $23M of tariff refunds tied to costs incurred during the first quarter.
GEHC's regular-session response was decisive. Shares climbed 10.06% to $70.56 on July 29, 2026, with volume well above the stated average. The price also moved above UBS's $69 target, a useful sign of how quickly a clean earnings beat can reset short-term market expectations.
The rating backdrop was constructive but not uniformly bullish. The consensus rating was Buy, based on 10 Buy ratings and 8 Holds, with no Sell or Strong Sell ratings. That distribution shows a favorable view of GEHC's business without broad analyst agreement that the stock deserves an aggressive upside case.
UBS moved GEHC to Neutral and cut its price target to $69 on May 21, 2026. BTIG reduced its target by $5 on July 13. Both actions came before the second-quarter results, when PCS execution and margin pressure remained central concerns. The latest EPS and revenue beat directly challenges the most cautious part of that setup, but the negative PCS EBIT result gives skeptics a concrete reason to stay disciplined.
The stock reaction therefore rewards the broad operating result rather than a complete turnaround. Investors received stronger orders, a larger backlog, and solid PDx and imaging growth. They also received evidence that PCS still needs operational repair and that free cash flow benefited from tariff refunds.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
GEHC Management Commentary: Growth, AI, and the PCS Repair
CEO Peter Arduini framed the quarter around demand, productivity, and product innovation. GEHC's customers face capacity limits and workflow problems, and Arduini positioned the company as a productivity partner rather than a simple equipment vendor.
“We're increasingly becoming a key productivity enabler for our customers as they navigate capacity constraints and workflow challenges.” - Peter Arduini, CEO, Earnings Call
That strategic message connects GEHC's devices, software, artificial intelligence tools, and service contracts. Arduini pointed to Photonova Spectra, True Definition DL, AI-enabled imaging upgrades, and subscription software as examples of expanding the value of the installed base. The approach can support both product pricing and recurring revenue when customers pay for software improvements instead of replacing an entire system.
“Orders increased 11%, with strong backlog, which grew $2.6 billion year-over-year, and book-to-bill of 1.15x, all of which were at record levels.” - Peter Arduini, CEO, Earnings Call
Arduini also offered a specific growth marker in Pharmaceutical Diagnostics. GEHC remains confident in a medium-term target of $500M or more in annual revenue by 2028. Flyrcado's dose growth and additional customer onboarding support that narrative, while demand for contrast media is close to outpacing total market supply.
“Fundamentally, it's the sum of all of these parts that gives us confidence in the remainder of the year and our medium-term outlook.” - Peter Arduini, CEO, Earnings Call
CFO Jay Saccaro focused on the numbers behind that confidence. He highlighted record orders, the $23.9B backlog, and the expected conversion of longer-cycle radiology orders into revenue in 2027. He also linked the second-half margin plan to pricing, cost control, supply improvements, and daily operating management.
“We started to see these improvements take hold in the second quarter and expect this to contribute more meaningfully to margin in the second half of the year and in 2027, even net of investments that we continue to make in the business.” - Jay Saccaro, CFO, Earnings Call
Saccaro's departure adds a management transition to the investment case. Arduini thanked him for three years of financial leadership, and George Newcomb will serve as interim CFO. That change does not alter the quarter's reported figures, but it places added importance on execution against the margin and cash-flow priorities Saccaro described.
The most credible near-term improvement target is PCS. Management expects better supply performance, sequential revenue improvement, and margin recovery in the second half. GEHC also expects FDA clearance for its premium anesthesia device in the second half of 2026, while CE marking for Photonova Spectra is expected during the same period.
GEHC earnings delivered the numbers the market wanted: an EPS and revenue beat, record orders, and strong PDx and imaging growth. The stock's climb reflects that strength, but the investment case still rests on PCS supply recovery, margin expansion, and cash flow without tariff refunds. If those repairs join the existing backlog and radiopharmaceutical momentum, GEHC has a credible path to stronger operating leverage.
GE HealthCare Technologies Inc. (GEHC) rose 10.06% after reporting adjusted EPS of $1.13 and revenue of $5.29 billion, both above estimates. Investors also reacted to 11.1% order growth, a 1.15x book-to-bill ratio, and a record $23.9 billion backlog.
+Did GEHC beat earnings and revenue estimates in the second quarter?
Yes, GEHC reported adjusted EPS of $1.13 versus the $1.04 estimate and revenue of $5.29 billion versus the $5.26 billion estimate. Adjusted EBIT was $750 million, producing a 14.2% margin.
+Which GE HealthCare segments performed best in the quarter?
Pharmaceutical Diagnostics was the standout, with 14.6% organic revenue growth and a 29.6% EBIT margin. Advanced Imaging Solutions also performed well, posting 5% organic growth and a 90-basis-point margin expansion year over year.
+What was the main weakness in GEHC's earnings report?
Patient Care Solutions was the weak spot, with organic revenue down 13.5% and segment EBIT turning negative. Management said it expects sequential improvement in the second half while it works on shipment velocity, supply execution, and backlog conversion.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on GEHC?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
